

Retraction

Retraction: Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma

Sijie Cheng¹, Tieling Li², Cheng Wang², Keyu Wang³, Chengcai Lai³, Jin Yan¹, Hongxia Fan¹, Fang Sun¹, Zhaohai Wang¹, Peirui Zhang¹, Linxiang Yu¹, Zhixian Hong¹, Guanglin Lei¹, Baijun Sun¹, Yuan Gao¹, Zhaohui Xiao¹, Xu Ji¹, Ruilan Wang¹, Jianzhong Wu¹, Xiliang Wang², Shaogeng Zhang¹ and Penghui Yang^{1,3}

¹Beijing 302 Hospital, Beijing, 100039, China

²Chinese PLA General Hospital, Beijing, 100853, China

³State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China

Published: January 16, 2024

Copyright: © 2024 Cheng et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: Multiple images in Figure 3C, which illustrates that LincRNA P7 inhibited the proliferation of HCC cells SMMC7721 and Huh7 with colony-forming assay, were found to be fraudulent duplications of images from a previously published Oncotarget paper [1] Figure 2D, which represents results of colony formation in different HCC cells Huh-6, BEL-7402 and SMMC-7721 transfected with unrelated HULC siRNA. As a result, all authors have agreed to the retraction of this paper from Oncotarget.

REFERENCE

1. Li SP, Xu HX, Yu Y, He JD, Wang Z, Xu YJ, Wang CY, Zhang HM, Zhang RX, Zhang JJ, Yao Z, Shen ZY. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. *Oncotarget*. 2016; 7:42431–46. <https://doi.org/10.18632/oncotarget.9883>. [PubMed]

Original article: *Oncotarget*. 2018; 9:36057–36066. <https://doi.org/10.18632/oncotarget.23282>